Medigene

OncologyGermanyNorthern Europe

Medigene

MediGene AG (MDG: DE) is a German biotechnology company established in 1994. It is involved in the development of drugs to treat pancreatic cancer.

MediGene AG (MDG: DE) is a German biotechnology company established in 1994. It is involved in the development of drugs to treat pancreatic cancer.

The company has two marketed products: Eligard for prostate cancer and Veregen for genital warts.

In January 2014 Medigene purchased fellow German group Trianta, which is developing a series of T cell-activating cancer vaccines.


Latest Articles

Back to top